In young PV/ET patients, the presence of either homozygous JAK2 mutation or chromatin/spliceosome/TP53 mutations is associated with a higher risk of disease progression, whereas DTA mutations predict arterial thrombosis. The gene discussed is TP53; the disease is essential thrombocythemia.